Literature DB >> 29126229

Osteoblast AMP-Activated Protein Kinase Regulates Postnatal Skeletal Development in Male Mice.

Ippei Kanazawa1, Ayumu Takeno1, Ken-Ichiro Tanaka1, Masakazu Notsu1, Toshitsugu Sugimoto1.   

Abstract

Studies have shown that AMP-activated protein kinase (AMPK), a crucial regulator of energy homeostasis, plays important roles in osteoblast differentiation and mineralization. However, little is known about in vivo roles of osteoblastic AMPK in bone development. Thus, to investigate in vivo roles of osteoblast AMPK, we conditionally inactivated Ampk in osterix (Osx)-expressing cells by crossing Osx-Cre mice with floxed AMPKα1 to generate mice lacking AMPKα1 in osteoblasts (Ampk-/- mice). Compared with wild-type and Ampk+/- mice, Ampk-/- mice displayed retardation of postnatal bone development, although bone deformity was not observed at birth. Microcomputed tomography showed significant reductions in trabecular bone volume, cortical bone length, and density, as well as increased cortical porosity in femur as well as development defects of skull in 8-week-old Ampk-/- mice. Surprisingly, histomorphometric analysis demonstrated that the number of osteoclasts was significantly increased, although bone formation rate was not altered. Loss of trabecular network connections and mass, as well as shortened growth plates and reduced thickness of cartilage adjacent to the growth plate, was observed in Ampk-/- mice. In primary cultured osteoblasts from calvaria, the expressions of alkaline phosphatase, type 1 collagen, osteocalcin, bone morphogenetic protein 2, Runx2, and osterix were significantly inhibited in Ampk-/- osteoblasts, whereas the expression of receptor activator of nuclear κB ligand (RANKL) and the RANKL/osteoprotegerin ratio were significantly increased. These findings indicate that osteoblastic AMPK plays important roles in bone development in vivo and that deletion of AMPK in osteoblasts decreases osteoblastic differentiation and enhances bone turnover by increasing RANKL expression.
Copyright © 2018 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29126229     DOI: 10.1210/en.2017-00357

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.

Authors:  Mark F McCarty; Lidianys Lewis Lujan; Simon Iloki Assanga
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

2.  Glucose Restriction Promotes Osteocyte Specification by Activating a PGC-1α-Dependent Transcriptional Program.

Authors:  Cristina Sánchez-de-Diego; Natalia Artigas; Carolina Pimenta-Lopes; José Antonio Valer; Benjamin Torrejon; Pau Gama-Pérez; Josep A Villena; Pablo M Garcia-Roves; José Luis Rosa; Francesc Ventura
Journal:  iScience       Date:  2019-04-12

3.  Microfibrillar-associated protein 5 regulates osteogenic differentiation by modulating the Wnt/β-catenin and AMPK signaling pathways.

Authors:  Haoran Li; Wuling Zhou; Shiwei Sun; Tianlong Zhang; Tieqi Zhang; Haitian Huang; Minghai Wang
Journal:  Mol Med       Date:  2021-12-05       Impact factor: 6.354

4.  Saxagliptin enhances osteogenic differentiation in MC3T3-E1 cells, dependent on the activation of AMP-activated protein kinase α (AMPKα)/runt-related transcription factor-2 (Runx-2).

Authors:  Qiang Wang; Xiaoxing Xie; Dehua Zhang; Feng Mao; Shaobo Wang; Yi Liao
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 5.  Metformin Prevents or Delays the Development and Progression of Osteoarthritis: New Insight and Mechanism of Action.

Authors:  Miao He; Bangbao Lu; Michael Opoku; Liang Zhang; Wenqing Xie; Hongfu Jin; Siyu Chen; Yusheng Li; Zhenhan Deng
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

6.  Effects of mild hyperbaric oxygen on osteoporosis induced by hindlimb unloading in rats.

Authors:  Ai Takemura; Paola Divieti Pajevic; Tatsuro Egawa; Rika Teshigawara; Tatsuya Hayashi; Akihiko Ishihara
Journal:  J Bone Miner Metab       Date:  2020-04-29       Impact factor: 2.626

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.